US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

1.780 -0.070 (-3.78%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Autolus Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Preview: Autolus Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Autolus Therapeutics ↗
 
Via Benzinga
News headline image
Earnings Outlook For Autolus Therapeutics ↗
 
Via Benzinga
News headline image
Why Autolus Therapeutics Stock Is Crashing Today ↗
The biopharmaceutical company announced the pricing of a secondary stock offering. 
Via The Motley Fool
News headline image
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
Via Benzinga
News headline image
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids
- Expanding the Autolus toolkit of T-cell engineering modules against complex and immunologically hostile cancers, including solid cancer applications 
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Host Virtual Capital Markets Day
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces Publication in Molecular Therapy
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics announces resignation of Chief Financial Officer
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Has No Business Relationship with Silicon Valley Bank
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Tesla To Rally More Than 12%? Here Are 10 Other Analyst Forecasts For Wednesday ↗
HC Wainwright & Co. cut the price target for DURECT Corporation (NASDAQ: DRRX) from $35 to $32. HC Wainwright & Co. analyst Ed Arce maintained a Buy rating. DURECT shares fell 1.3% to close at $4.75 on... 
Via Benzinga
News headline image
Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics announces Board changes
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus’ Safety Switch System in Cell Therapies for Autoimmune Disease
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSs
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Dow Tumbles 100 Points; Silver Rises Over 2% ↗
U.S. stocks traded mostly lower toward the end of trading with the Dow Jones dropping 100 points on Friday 
Via Benzinga
News headline image
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate. 
Via Benzinga
News headline image
US Stocks Turn Higher; Nasdaq Rises 40 Points ↗
U.S. stocks traded slightly midway through trading with the Nasdaq gaining over 40 points on Friday 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >